Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 4;67(2):514–523. doi: 10.1002/hep.29541

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors and AbbVie. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

SURVEYOR‐II, Part 3 study design. Patients were enrolled into two arms to be treated with either 12 weeks (arm A) or 16 weeks (arm B) of G/P. Treatment‐naive patients with cirrhosis received 12 weeks of treatment, while those with prior treatment experience and cirrhosis received 16 weeks. Patients with prior treatment experience but without cirrhosis were randomized 1:1 for treatment with either 12 or 16 weeks of G/P. Patients were followed for 24 weeks posttreatment to monitor safety and sustained virologic response. Abbreviations: TE, treatment‐experienced; TN, treatment‐naive.